BRPI0919290A2 - composto de imidazoldina com moduladores de receptor de androgênio, e composição farmacêutica - Google Patents
composto de imidazoldina com moduladores de receptor de androgênio, e composição farmacêuticaInfo
- Publication number
- BRPI0919290A2 BRPI0919290A2 BRPI0919290-5A BRPI0919290A BRPI0919290A2 BR PI0919290 A2 BRPI0919290 A2 BR PI0919290A2 BR PI0919290 A BRPI0919290 A BR PI0919290A BR PI0919290 A2 BRPI0919290 A2 BR PI0919290A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- androgen receptor
- receptor modulators
- imidazoldine
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19191808P | 2008-09-11 | 2008-09-11 | |
US61/191,918 | 2008-09-11 | ||
GB0900333.6A GB2463514C (en) | 2008-09-11 | 2009-01-09 | Imidazolidine compounds and uses therefor |
GB0900333.6 | 2009-01-09 | ||
PCT/EP2009/061733 WO2010029119A1 (en) | 2008-09-11 | 2009-09-10 | Novel imidazolidine compounds as androgen receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0919290A2 true BRPI0919290A2 (pt) | 2019-04-30 |
Family
ID=40379370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0919290-5A BRPI0919290A2 (pt) | 2008-09-11 | 2009-09-10 | composto de imidazoldina com moduladores de receptor de androgênio, e composição farmacêutica |
Country Status (20)
Country | Link |
---|---|
US (2) | US7968581B2 (pt) |
EP (1) | EP2344460B1 (pt) |
JP (1) | JP5595402B2 (pt) |
KR (1) | KR101705157B1 (pt) |
CN (1) | CN102149687B (pt) |
AR (1) | AR073282A1 (pt) |
AU (1) | AU2009290849B2 (pt) |
BR (1) | BRPI0919290A2 (pt) |
CA (1) | CA2736364C (pt) |
CO (1) | CO6382130A2 (pt) |
ES (1) | ES2552684T3 (pt) |
GB (1) | GB2463514C (pt) |
HK (1) | HK1141015A1 (pt) |
IL (1) | IL211277A (pt) |
MX (1) | MX2011002374A (pt) |
NZ (1) | NZ591374A (pt) |
RU (1) | RU2488584C2 (pt) |
TW (1) | TWI449698B (pt) |
WO (1) | WO2010029119A1 (pt) |
ZA (1) | ZA201101707B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168667B2 (en) * | 2006-05-31 | 2012-05-01 | Galapagos Nv | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such |
BR112013023028B1 (pt) | 2011-03-10 | 2021-09-21 | Suzhou Kintor Pharmaceuticals, Inc | Composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e formulação farmacêutica tópica |
GB201311107D0 (en) * | 2013-06-21 | 2013-08-07 | Univ Edinburgh | Bioorthogonal methods and compounds |
EP3021841B1 (en) * | 2013-07-18 | 2022-11-16 | Baylor College Of Medicine | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia |
CN105979943A (zh) * | 2013-10-25 | 2016-09-28 | 厄恩斯特.D.布什 | 肌营养不良的治疗方法 |
CN106573921B (zh) * | 2013-12-31 | 2019-05-07 | 博福-益普生(天津)制药有限公司 | 咪唑烷-2,4-二酮衍生物 |
US11662606B2 (en) * | 2017-12-06 | 2023-05-30 | Eyebright Medical Technology (Beijing) Co., Ltd. | Orthokeratology lens and method for making orthokeratology lenses |
EP3773537B1 (en) | 2018-04-19 | 2022-03-23 | Tvardi Therapeutics, Inc. | Stat3 inhibitors |
US11026905B2 (en) | 2018-04-19 | 2021-06-08 | Tvardi Therapeutics, Inc. | STAT3 inhibitors |
EP4093377A1 (en) | 2020-01-24 | 2022-11-30 | Tvardi Therapeutics, Inc. | Therapeutic compounds, formulations, and uses thereof |
CN113024513A (zh) * | 2021-03-22 | 2021-06-25 | 中国药科大学 | 新型雄激素受体降解剂、制备方法和医药用途 |
CN113801064A (zh) * | 2021-09-26 | 2021-12-17 | 甘肃省化工研究院有限责任公司 | 一种[3+2]环加成反应构建苯基乙内酰脲的方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5136332B1 (pt) * | 1970-12-09 | 1976-10-07 | ||
GB1601310A (en) * | 1978-05-23 | 1981-10-28 | Lilly Industries Ltd | Aryl hydantoins |
DE2855770A1 (de) | 1978-12-22 | 1980-07-10 | Bayer Ag | Hydantoine |
US4753957A (en) | 1981-09-28 | 1988-06-28 | Rohm And Haas Company | Substituted 2,4-imidazolidinediones and fungicidal compositions |
EP0091596B1 (de) | 1982-04-08 | 1991-09-11 | Shell Internationale Researchmaatschappij B.V. | Neue Hydantoine, ihre Herstellung und Verwendung |
FR2619381B1 (fr) * | 1987-08-13 | 1989-12-08 | Roussel Uclaf | Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation |
JP2566792B2 (ja) | 1987-09-30 | 1996-12-25 | 株式会社資生堂 | 発毛、養毛促進剤 |
JPH0219363A (ja) | 1988-07-06 | 1990-01-23 | Fujisawa Pharmaceut Co Ltd | イミダゾリジン誘導体 |
US4992443A (en) | 1990-03-12 | 1991-02-12 | William Chelen | Method of treating motion sickness |
US5346913A (en) | 1992-05-26 | 1994-09-13 | Rohm And Haas Company | N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents |
JP3137430B2 (ja) | 1992-06-10 | 2001-02-19 | 鐘淵化学工業株式会社 | 5,5−二置換ヒダントインの製造法 |
US6846525B2 (en) | 1993-03-19 | 2005-01-25 | Xerox Corporation | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds |
FR2715402B1 (fr) * | 1994-01-05 | 1996-10-04 | Roussel Uclaf | Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
TW521073B (en) * | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
CA2188427C (en) | 1994-04-29 | 2000-06-27 | Robert A. Volkmann | Neurotransmitter release enhancers |
EP0760239A3 (en) | 1995-09-01 | 1999-04-14 | Pfizer Inc. | Therapeutic agents for use in cancer therapy |
FR2741342B1 (fr) * | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
BR9811260A (pt) | 1997-03-03 | 2000-08-08 | Boehringer Ingelheim Pharma | Pequenas moléculas úteis no tratamento de doença inflamatória |
US6355664B1 (en) | 1997-03-03 | 2002-03-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease |
UA57081C2 (uk) | 1997-06-16 | 2003-06-16 | Пфайзер Продактс Інк. | Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування |
US6492553B1 (en) | 1998-01-29 | 2002-12-10 | Aventis Pharamaceuticals Inc. | Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds |
EP0945441A3 (de) | 1998-03-27 | 2002-07-17 | Degussa AG | Verfahren zur Herstellung von cyclischen 4-Oxoamidinen |
HUP0302002A3 (en) | 2000-05-11 | 2007-02-28 | Consejo Superior Investigacion | Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them |
US6846643B2 (en) | 2000-08-14 | 2005-01-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods and molecules useful for identifying molecules that bind LFA-1 and for determining receptor occupancy |
JP5031568B2 (ja) * | 2004-09-10 | 2012-09-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 選択的アンドロゲン受容体モジュレーター(sarms)としての新規なイミダゾリジン−2−オン誘導体 |
CN101304976A (zh) | 2005-10-11 | 2008-11-12 | 因特蒙公司 | 病毒复制抑制剂 |
GB0610765D0 (en) * | 2006-05-31 | 2006-07-12 | Proskelia Sas | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such |
-
2009
- 2009-01-09 GB GB0900333.6A patent/GB2463514C/en not_active Expired - Fee Related
- 2009-09-09 AR ARP090103461A patent/AR073282A1/es unknown
- 2009-09-10 JP JP2011526487A patent/JP5595402B2/ja not_active Expired - Fee Related
- 2009-09-10 KR KR1020117007686A patent/KR101705157B1/ko active IP Right Grant
- 2009-09-10 CN CN200980135475.9A patent/CN102149687B/zh not_active Expired - Fee Related
- 2009-09-10 CA CA2736364A patent/CA2736364C/en not_active Expired - Fee Related
- 2009-09-10 RU RU2011113749/04A patent/RU2488584C2/ru not_active IP Right Cessation
- 2009-09-10 AU AU2009290849A patent/AU2009290849B2/en not_active Ceased
- 2009-09-10 US US12/557,368 patent/US7968581B2/en active Active
- 2009-09-10 EP EP09782854.5A patent/EP2344460B1/en active Active
- 2009-09-10 WO PCT/EP2009/061733 patent/WO2010029119A1/en active Application Filing
- 2009-09-10 MX MX2011002374A patent/MX2011002374A/es active IP Right Grant
- 2009-09-10 BR BRPI0919290-5A patent/BRPI0919290A2/pt not_active Application Discontinuation
- 2009-09-10 ES ES09782854.5T patent/ES2552684T3/es active Active
- 2009-09-10 NZ NZ591374A patent/NZ591374A/en not_active IP Right Cessation
- 2009-09-11 TW TW098130825A patent/TWI449698B/zh not_active IP Right Cessation
-
2010
- 2010-08-02 HK HK10107354.3A patent/HK1141015A1/xx not_active IP Right Cessation
-
2011
- 2011-02-17 IL IL211277A patent/IL211277A/en not_active IP Right Cessation
- 2011-03-04 ZA ZA2011/01707A patent/ZA201101707B/en unknown
- 2011-04-08 CO CO11043783A patent/CO6382130A2/es not_active Application Discontinuation
- 2011-06-23 US US13/167,682 patent/US8383608B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0919290A2 (pt) | composto de imidazoldina com moduladores de receptor de androgênio, e composição farmacêutica | |
BR112012000968B8 (pt) | composto, composição e método para inibir uma fosfatidil inositol-3 cinase. | |
BR112012010253A2 (pt) | compostos de pirimidina como moduladores do receptor delta opioide | |
BR112012027915A2 (pt) | nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo | |
BR112012024822B8 (pt) | Composto, uso de um composto e composição farmacêutica | |
UY32571A (es) | Compuestos derivados de pirazol amida | |
BRPI1012082A2 (pt) | composição aquosa , método para preparar um composição de igg concentrada a partir de plasma , e, uso da composição. | |
BR112013005141A2 (pt) | diazetidinil diamida como inibidores de monoacilglicerol lipase | |
BR112012017564A2 (pt) | Formulação antimicrobiana | |
CL2009000650A1 (es) | Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras | |
BR112013031268A8 (pt) | polipeptídeos | |
BRPI1008383A2 (pt) | composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto | |
DOP2011000128A (es) | Aminotethahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes | |
BR112014021531A8 (pt) | composto, composição farmacêutica e usos dos mesmos | |
CR20110509A (es) | Composicion farmaceutica | |
GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
BR112012012903A2 (pt) | compostos de espiropiperidina | |
CL2013002664A1 (es) | Compuestos derivados heterociclicos de amina; afines a receptores asociados a mina traza taar1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la depresion, ansiedad, parkinson, trastorno bipolar, de hiperactividad con deficit atencional, relacionados con estres, y otros. | |
CL2007001022A1 (es) | Compuestos derivados de 1h-indol-2-carboxamida; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento y/o prevencion de enfermedades asociadas con la modulacion de los receptores de h3 tal como obesidad, diabetes tipo ii y | |
BRPI0911031B8 (pt) | compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes | |
BRPI0815591B8 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
GT201100198A (es) | Nuevos herbicidas | |
CL2015000289A1 (es) | Compuesto citostatico derivado de niclosamida y compuesto alquilante derivado de 2,3,4,6,8-pentazabiciclo[4.3.0]nona-2,7-trieno; composicion farmaceutica que los comprende; y metodo para determinar si el tratamiento para un paciente con un tumor solido es adecuado. | |
CO7160013A2 (es) | Derivados de amida cíclica como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa y los usos de los mismos | |
BRPI1008039A2 (pt) | composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B25C | Requirement related to requested transfer of rights |
Owner name: GALAPAGOS N.V. (BE) Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 20130032114 DE 15/04/2013, E NECESSARIO APRESENTAR O DOCUMENTO DE CESSAO NOTARIZADO E COM APOSTILAMENTO OU LEGALIZACAO CONSULAR, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA. |
|
B25A | Requested transfer of rights approved |
Owner name: DART THERAPEUTICS, LLC (US) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |